

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/508,510	05/26/2000	MICHAEL TSCHOPE	P100564-0000	7619
6449	7590 01/08/2004		EXAMINER	
ROTHWELL, FIGG, ERNST & MANBECK, P.C. 1425 K STREET, N.W.			MERTZ, PREMA MARIA	
SUITE 800	<i>L</i> 1,11.W.		ART UNIT	PAPER NUMBER
WASHINGTO	ON, DC 20005		1646	

DATE MAILED: 01/08/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Advisory Action	09/508,510	TSCHOPE ET AL.			
,	Examiner	Art Unit			
	Prema M Mertz	1646			
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress		
THE REPLY FILED FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.					
PERIOD FOR RE	EPLY [check either a) or b)]				
a) The period for reply expires 6 months from the mailing date	-				
b)  The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	ater than SIX MONTHS from the mailing	g date of the final rejecti	on.		
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
<ul><li>1. A Notice of Appeal was filed on 23 <u>December 2003</u>.</li><li>37 CFR 1.192(a), or any extension thereof (37 CFF)</li></ul>			forth in		
2. The proposed amendment(s) will not be entered be	ecause:				
(a) X they raise new issues that would require further	er consideration and/or search (s	see NOTE below);			
(b) they raise the issue of new matter (see Note b	elow);				
(c)  they are not deemed to place the application ir issues for appeal; and/or	n better form for appeal by mater	rially reducing or sir	nplifying the		
(d)  they present additional claims without canceling	ng a corresponding number of fi	nally rejected claim	s.		
NOTE: See Continuation Sheet.					
3. Applicant's reply has overcome the following rejecti	ion(s): See Continuation Sheet.				
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed	amendment		
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:		dered but does NO	Γ place the		
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were	e newly		
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims wo			nd an		
The status of the claim(s) is (or will be) as follows:					

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03)

10. Other: \_\_\_\_

Claim(s) allowed: \_\_\_\_\_.
Claim(s) objected to: \_\_\_\_\_.

Claim(s) rejected: 1-14,17-23 and 25-31.

Claim(s) withdrawn from consideration: \_\_\_\_\_.

8. The drawing correction filed on \_\_\_\_ is a) approved or b) disapproved by the Examiner.

9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s). \_\_\_\_\_.

Prema M Mertz Primary Examiner Art Unit: 1646 Continuation of 2. NOTE: The recitation of "the" inhibition in amended claims 1, 3, and 26 precipitates a 35 USC 112, second paragraph rejection because there is no antecedent basis for this limitation in the claims. Furthermore, claims 1-2, 4-8, 13-14, 21-23 remain rejected under 35 U.S.C. 102 (b) as being anticipated by EP 0529300 because the claims fail to recite that there are no additional stabilizers in the formulation and therefore the references disclosure of a formulation comprising the stabilizer human serum albumin anticipates the claims. Additionally, claims 1-14, 17-23, 25-31 remain rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0529300 in view of Patel (U.S. Patent No. 5,358,708) for reasons of record because the combination of the references renders obvious the instant claims.

Continuation of 3. Applicant's reply has overcome the following rejection(s): the 35 USC 112, second para rejection for reciting "in vitro biological activity".